Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, Utah 81407, USA.
J Heart Lung Transplant. 2012 Feb;31(2):180-6. doi: 10.1016/j.healun.2011.11.018.
Nearly 25% of patients with peripartum cardiomyopathy (PPCM) will require cardiac transplantation. Whether post-transplant outcomes differ among patients with PPCM compared with other recipients remains unsettled.
The United Network for Organ Sharing database was queried for cardiac transplants, comparing characteristics and outcomes for PPCM, other women, and all others.
Between 1987 and 2010, 42,406 patients (9,419 women and 32,987 men) received a heart transplant. Of these, 485 women who had PPCM as the indication were younger (p < 0.001), had higher sensitization (p < 0.001), required higher intensity of cardiovascular support pre-transplant (p = 0.026), and had higher listing status (p < 0.001). Those with PPCM had more post-transplant rejection during the index transplant hospitalization (p < 0.001) and during the first year (p = 0.003). Comparing PPCM with other women and all others, graft survival was inferior (p = 0.004 and p < 0.003, respectively) and age-adjusted survival was lower (p < 0.001 and p = 0.02, respectively).
This large report shows outcomes of graft failure and death are inferior for recipients with PPCM, which may be partly explained by younger age, higher allosensitization, higher pre-transplant acuity, and increased rejection. More research is needed to determine management strategies to improve outcomes in PPCM heart transplant recipients.
近 25%的围产期心肌病(PPCM)患者需要进行心脏移植。接受心脏移植的 PPCM 患者与其他患者相比,移植后结局是否存在差异仍未确定。
本研究在美国器官共享联合网络数据库中检索心脏移植患者资料,比较 PPCM、其他女性和所有其他患者的特征和结局。
1987 年至 2010 年间,42406 名患者(9419 名女性和 32987 名男性)接受了心脏移植。其中,485 名女性因 PPCM 接受移植,这些患者更年轻(p<0.001)、致敏率更高(p<0.001)、移植前心血管支持强度更高(p=0.026)、等待移植状态更高(p<0.001)。与其他女性和所有其他患者相比,PPCM 患者在索引移植住院期间(p<0.001)和移植后第一年(p=0.003)的移植后排斥反应更多。与其他女性和所有其他患者相比,PPCM 患者的移植物存活率更低(p=0.004 和 p<0.003),年龄调整后存活率更低(p<0.001 和 p=0.02)。
本研究报道了患者因 PPCM 接受心脏移植后,移植物衰竭和死亡的结局较差,其原因可能与患者更年轻、更高的致敏率、更高的移植前疾病严重程度和更多的排斥反应有关。需要进一步研究以确定改善 PPCM 心脏移植患者结局的管理策略。